Showing 1381-1390 of 2007 results for "".
- New Peptide Serum Complements In-Office Aesthetic Treatmentshttps://modernaesthetics.com/news/new-peptide-serum-complements-in-office-aesthetic-treatments/2485257/ZO® Skin Health has introduced the Peptide Facial Refining Concentrate, an advanced at-home serum formulated to complement professional aesthetic procedures and enhance overall facial rejuvenation. The launch adds to the company’s physician-dispensed portfolio with
- FDA: Most PFAS in Cosmetics Lack Adequate Safety Datahttps://modernaesthetics.com/news/fda-most-pfas-in-cosmetics-lack-adequate-safety-data/2485144/The U.S. Food and Drug Administration (FDA) announced that it has released its first congressionally mandated report under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), assessing the use and safety of perfluoroalkyl and polyfluoroalkyl substances (PF
- New Simulation Study Suggests BoNT/A Restrictions May Be Overly Conservativehttps://modernaesthetics.com/news/new-simulation-study-suggests-bonta-restrictions-may-be-overly-conservative/2485067/A large-scale, simulation-based study challenges the long-standing 4-hour restriction on post-injection activity following botulinum neurotoxin A (BoNT/A) treatment, suggesting that everyday behaviors may have minimal impact on toxin spread. The study, published in Scientific Reports, em
- Senolytic Skincare Platform Backed by First Peer-Reviewed Studyhttps://modernaesthetics.com/news/senolytic-skincare-platform-backed-by-first-peer-reviewed-study/2485088/Robles BioCeutics, a regenerative dermatology company focused on senolytic and stem cell–inspired approaches, has published its first peer-reviewed article in The Journal of Translational Medicine, validating the scientific basis of its proprietary skin regeneration platform. The
- FDA Clears Cutera truFlex® for Muscle Rehab, Recovery, and Post-Surgical Usehttps://modernaesthetics.com/news/fda-clears-cutera-truflex-for-muscle-rehab-recovery-and-post-surgical-use/2485023/Cutera, Inc. has announced that its truFlex® muscle stimulation system has received expanded US Food and Drug Administration (FDA) clearances for use in rehabilitation, recovery, and muscle wellness applications. Originally cleared for aesthetic body contouring, the system can now be used to stre
- New Study Supports Efficacy of Noninvasive Ultrasound for Cellulitehttps://modernaesthetics.com/news/new-study-supports-efficacy-of-noninvasive-ultrasound-for-cellulite/2485014/A novel ultrasound-based device featuring synchronous parallel beam technology with a high-density handpiece demonstrated significant improvement in the appearance of cellulite, according to findings from a new multicenter study published in Dermatologic Surgery. The open-label, n
- AAFPRS Issues Alert Regarding Rise of Counterfeit Neuromodulatorshttps://modernaesthetics.com/news/aafprs-issues-alert-regarding-rise-of-counterfeit-neuromodulators/2484932/The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) has released a warning to consumers to remain vigilant as counterfeit and unapproved neuromodulators continue to enter the aesthetic medicine market. The AAFPRS issued the warning after the US Food and Drug Administration
- AI-Guided Ultrasound Enhances Safety of Thread Lifting with Energy-Based Deviceshttps://modernaesthetics.com/news/ai-guided-ultrasound-enhances-safety-of-thread-lifting-with-energy-based-devices/2484656/Thread lifting using poly-L-lactic acid (PLLA) and polycaprolactone (PCL) sutures appears to be safe when performed under artificial intelligence (AI)-guided high-frequency ultrasound—even when combined with energy-based modalities on the same day, according to a new retrospective study published
- RVL Pharmaceuticals Announces New CEO, Chief Growth Officerhttps://modernaesthetics.com/news/rvl-pharmaceuticals-announces-new-ceo-chief-growth-officer/2484615/RVL Pharmaceuticals, Inc. has appointed Lori Deo as Chief Executive Officer and Amy Shah as Chief Growth Officer, signaling a strategic leadership shift aimed at accelerating growth for its lead product, Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1%. Deo, who previously se
- Platform Prints First Collagen-Based Bioink for Personalized Tissue Creationhttps://modernaesthetics.com/news/platform-prints-first-collagen-based-bioink-for-personalized-tissue-creation/2484559/Conexeu Sciences Inc. has announced the first 3D-printed tissue scaffolds created entirely from its proprietary extracellular matrix (ECM), according to a release from the manufacturer. Conexeu said their CXU™ platform, a bovin